Cargando…

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure

Concomitant type 2 diabetes and chronic kidney disease increases the risk of heart failure. Recent studies demonstrate beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on chronic kidney disease progression and heart failure hospitalization in patients with and without diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales:	BJORNSTAD, PETTER, GREASLEY, PETER J., WHEELER, DAVID C., CHERTOW, GLENN M., LANGKILDE, ANNA MARIA, HEERSPINK, HIDDO J.L., VAN RAALTE, DANIËL H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759453/ https://www.ncbi.nlm.nih.gov/pubmed/34289398 http://dx.doi.org/10.1016/j.cardfail.2021.07.003

Ejemplares similares

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes
por: van Raalte, Daniël H, et al.
Publicado: (2020)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2021)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

GMP Compliant Synthesis of [(18)F]Canagliflozin, a Novel PET Tracer for the Sodium–Glucose Cotransporter 2
por: van der Hoek, Sjoukje, et al.
Publicado: (2021)

Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial
por: Vart, Priya, et al.
Publicado: (2023)

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction
por: Peng, Xiaodong, et al.
Publicado: (2020)

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
por: Veenit, Vandana, et al.
Publicado: (2023)

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure
por: Grubić Rotkvić, Petra, et al.
Publicado: (2020)

Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
por: Dutka, Mieczysław, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease
por: Shivakumar, Oshini, et al.
Publicado: (2020)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes
por: Mulder, Skander, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors: a practical guide for the Dutch cardiologist based on real-world experience
por: Zwart, K., et al.
Publicado: (2021)

Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
por: Naito, Ryo, et al.
Publicado: (2021)

Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu
Publicado: (2021)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
por: Cao, Yang, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?
por: McDowell, Kirsty, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s26bv820poqe3h0v0mejmoens9